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Antiretroviral therapy (ART) is intended
to maintain durable HIV viral load sup-
pression, allowing immunological recov-
ery.This results in a greatly reduced risk
of HIV-related illness. These benefits can
only be obtained by combining at least
three antiretroviral drugs, known as highly
active antiretroviral therapy (HAART).
Successful therapy is critically dependent
on the HIV clinician and the patient
establishing a robust therapeutic relation-
ship.The prescribing doctor must take
responsibility for advising the patient on
the choice of ART and for supporting the
patient on therapy. Incorrect combina-
tions or dosing can lead to failure of ther-
apy and subsequent development of viral
resistance.The patient must accept the
need for long-term adherence to medica-
tion and should understand both the risks
and benefits offered by ART.
Poor management can deprive a patient of
the chance to derive long-term benefit
from HAART.
WHEN TO START HAART — 
GETTING IT IN PERSPECTIVE
Clinical criteria for commencing therapy,
that is HIV stage and CD4 count, should
follow the latest South African HIV
Clinicians Society Guidelines, as should
the drug regimen chosen (Tables I and
II). Clinicians and patients frequently
either find it difficult to accept that thera-
py can be safely postponed for many years
or worry unduly about the risks and side-
effects associated with HAART.
Timing, benefits and risks can be put into
perspective by telling a story:
Some patients, despite fitting the clinical
criteria exactly, do not do well on therapy.
Picking these people out in advance is
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Imagine you are hiking through the
bushveld and enjoying the bird life and the
game. But, in the distance, you see a lion
stalking you. You aren’t too worried
because you have a gun.But there are only
two bullets in the gun,so you need to be
quite sure about the best time to shoot.If
you shoot too soon there is a good chance
that you will miss the lion,and that the
explosion will chase away all the wildlife. If
you leave it too late the lion may be on top
of you before you can take aim.
The lion represents AIDS and the distance
between you and the lion shows how strong
your immune system is — the closer the
lion the weaker your immune system.The
gun with two bullets is your antiretroviral
therapy, which you need to learn how to
use properly so that you don’t hurt yourself.
The sound of the gun being fired represents
the potential side-effects from the antiretro-
viral therapy — a real nuisance if the lion
is far away, but the last thing you’d worry
about when the lion is getting close!
Antiretroviral therapy needs to be used
responsibly.
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Symptomatic patient (excluding TB) Treatment
Presence of HIV-related symptoms, current or Treatment recommended 
previous HIV-associated disease (includes AIDS-defining
illnesses, unexplained weight loss >10%, unexplained 
diarrhoea >1 month, oral candidiasis or oral hairy
leukoplakia)
Patient with tuberculosis
CD4 count <200 cells/µl Delay treatment until after 2-month 
intensive phase of TB treatment unless the 
patient has other serious HIV-related illness  
or a CD4 count <50 cells/µl, when ART
should be introduced as soon as the 
patient is stabilised
CD4 count >200 cells/µl Commence therapy after completing 
6 months of TB therapy. Consider 
CD4 guidelines below if asymptomatic 
once TB treatment completed.
Asymptomatic patient
CD4 count <200 cells/µl Treatment recommended
CD4 count 200 - 350 cells/µl Monitor CD4 count: if count decreases 
in excess of the expected 20 - 80 cells 
per year or count approaches 
200, commence therapy
CD4 count >350 cells/µl Defer treatment
Table I. Clinical reasons to commence ART
Category I Category II Category III Category IV Category V
(NRTIs) (NRTIs) (NRTI) (NNRTIs) (PIs)
Stavudine Didanosine Abacavir Nevirapine Nelfinavir
(d4T) (ddI) (ABC) (NVP) (NFV)
Zidovudine Lamivudine Efavirenz† Indinavir/RTV
(AZT) (3TC) (EFV) (IDV)
Zalcitabine Saquinavir/RTV






NRTI = nucleoside reverse transcriptase inhibitor; N NRTI = non- nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
*For initiation of therapy in an ART-naïve patient use 2 N RTIs (one from category I and one from category II) together with one NNRTI (category IV).
† EFV is teratogenic. Avoid in women of childbearing potential. Only use if no other ART available and patient can guarantee hormonal contraception is used as well as barri-
er methods.
‡ RTV is most often used in combination with another protease inhibitor at a low dose of 100 mg twice daily. Here it is being used as a p450 inhibitor to boost the levels of
the combined PI. It is not a useful antiretroviral agent at this low dose. In adults it is rarely used as an antiretroviral in its own right (600 mg twice daily) due to increased
adverse events (e.g. diarrhoea).
Table II. Options for ART*
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close to impossible.There are,
however, certain patient-related
factors which make adherence less
likely and which should be
addressed before starting HAART:
• The patient must have come to
terms with being infected with
HIV — do not start therapy in
someone with a recent diagnosis.
Patients who have adjusted to
their HIV status should be com-
fortable enough to disclose to
chosen friends or family mem-
bers. Non-disclosure predicts treat-
ment failure.
• Patients should have good
understanding of HIV disease
and progression to immune sys-
tem failure and AIDS.
• Similarly they should have a
basic understanding of the
action of antiretrovirals, and be
willing to learn about the med-
ication they are planning to
take.
• Significant depression makes
adherence to ART difficult.
Psychotherapy and an antide-
pressant may be necessary
before embarking on HAART.
• The personal and social disrup-
tion associated with drug and
alcohol abuse makes long-term
adherence to a HAART regimen
problematic.
PRE-THERAPY INPUT
HAART never needs to be started
as a matter of urgency. Educating
the patient about HAART before
beginning therapy is worth the
time. Key points for the patient
are:
• HAART is for life.There are no
breaks or holidays — in fact
treatment interruptions can be
detrimental to long-term suc-
cess. Viral suppression hinges on
maintaining adequate drug lev-
els in the blood.
• Dual nucleoside combinations
are best avoided, as they are
unable to deliver long-term ben-
efit.
• The first HAART regimen is
the one most likely to have suc-
cess. Once exposed to ART,
subsequent regimens have a
poorer outcome. Make your first
regimen work for you.
• Missing even one dose a week
can result in treatment failure
and viral resistance over time.
Do not start therapy if you are not
ready to make a full commitment
to daily therapy for life.
• Do not stop any of your medica-
tions without consulting your
doctor. If stopping is unavoid-
able (e.g. due to a side-effect),
stop all three medications togeth-
er. (Note that non-nucleoside
reverse transcriptase inhibitors
(NNRTIs) have a very long half-
life, and should ideally be
stopped 4 days before the nucle-
oside reverse transcriptase
inhibitors (NRTIs)). Ask your
doctor what side-effects may be
expected.
• When a dose is twice a day it
means 12 hours apart (e.g. 8 am
and 8 pm). Once a day means
24 hours apart. Sticking as close
as possible to these dosing inter-
vals is important for viral sup-
pression.
• Get food restrictions right: if a
tablet, e.g. ddI (Videx), needs to
be taken on an empty stomach,
an hour before eating, do that. If
you don’t the drug may not be
absorbed.
• Check that any other medica-
tion you are prescribed does not
interact with your ART.
WHICH DRUGS TO USE
Ideally triple antiretroviral regi-
mens should be tailored to individ-
ual patients:
• Keep it simple — avoid three
times daily dosing as people fre-
quently don’t take the midday
dose. Most medications can be
taken once or twice daily (for
example 800 mg of indinavir
can be ‘boosted’ with 100 mg of
ritonavir, which extends the dos-
ing interval from 8 to 12
hourly). Note potential side-
effects — do not choose drugs
that might exacerbate existing
clinical problems e.g. liver dis-
ease, peripheral neuropathy or
hyperlipidaemia.
• Watch the practicalities of dos-
ing — complex food restrictions
should be kept to a minimum.
Be careful about drug interac-
tions (e.g. is the patient on
antiepileptics, rifampicin, flu-
conazole, erythromycin or pep-
tic ulcer therapy?)
• Keep the daily number of
tablets low — remember supple-
ments add up too.
• The patient’s budget is a crucial
factor in the decision-making
process. ART is expensive so
don’t push the patient into an
unaffordable regimen. Many ini-
tiatives are underway to broaden
access to HAART.
GETTING GOING
• Initially offer increased visits, at
least once a month. People
starting nevirapine need liver
functions monitored at 2, 4 and
6 weeks. Make the most of the
visit — discuss how many doses
have been missed over the past
three days and why, and resolve
any issues which can negatively
affect adherence.
• Watch out for side-effects.
Encourage your patient to come
to you before stopping the med-
ication. Minor adverse events,
such as ongoing nausea, can
prevent adherence. Pay attention
to these seemingly ‘unimpor-
tant’ issues.
• Support groups are beneficial.
Encourage your patient to see a
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counsellor regularly or join a
support group. Discussion pro-
vides emotional and practical
support.
• Ask the patient to select a treat-
ment partner from among the
people to whom he/she has dis-
closed.This partner can assist
by reminding the patient to take
his/her medication, and by pro-
viding emotional support.
He/she may also be able to add
insight into the home circum-
stances of the patient.
The following case histories high-
light some of the important prob-




A 31-year-old woman presents to
the surgery, having been diagnosed
with HIV 18 months previously
following recurrent bouts of vagi-
nal candidiasis. Her CD4 count at
diagnosis was 310 cells/mm3.
At the time of diagnosis, she
declared herself not yet ready to
begin antiretrovirals, and she has
been managed by you with ongo-
ing counselling, intercurrent dis-
ease management, and 6-monthly
CD4 counts.
At this visit, her CD4 count is 204
cells/mm3, and she requests that
she begin antiretroviral therapy. An
HIV viral load reveals a level of
110 000 copies/ml. A baseline ALT
reveals a level of 42 U/l.
Following adherence counselling,
she is started on:
• D4T 40 mg po bd (weight 68
kg)
• 3TC 150 mg po bd
• nevirapine 200 mg po/day to
increase to 200 mg po bd at 2
weeks.
On day eight of therapy she con-
tacts the surgery complaining of
diffuse pruritus and a rash. She is
asked to come in, and examination
reveals her to have a diffuse macu-
lopapular rash, with no evidence of
systemic symptoms, mucosal
lesions, or fever. In consultation
with the patient, it is decided to
continue the treatment, but to add
oral chlorpeniramine (4 mg orally
tds) for symptomatic relief . An
ALT is sent to check for possible
hepatitis.This comes back within
the normal range at 38 U/l. On day
13, the rash has resolved, and the
symptomatic treatment is stopped.
For safety reasons, the dose step-
up of nevirapine is delayed for 1
week, and on day 21 of therapy she
increases her nevirapine to 200 mg
bd.
At three months her CD4 count is
270 cells/mm3, and her viral load is
less than 400 copies/ml. She is
booked for further 6-monthly
assessments.
This case demonstrates several
important facts about commencing
antiretroviral therapy in antiretrovi-
ral-naïve patients:
• The most important factor is
patient acceptance, and coun-
selling regarding high-level regi-
men compliance. No regimen
should be started without atten-
tion to this aspect.
• The sequence of drugs used fol-
lows a fairly typical pattern. A
backbone of NRTI agents (one
thymidine analogue — D4T;
one non-thymidine analogue —
3TC) is utilised, and a third
highly active agent (NNRTI
class — nevirapine) is added to
complete the regimen.
• Early side-effects tend to occur
in the first 2 - 6 weeks of thera-
py, and are generally mild to
moderate. Most can be man-
aged without stopping the regi-
men.
CASE 2: CHANGING THER-
APY AFTER FIRST-LINE
THERAPY FAILURE
A 29-year-old man, well known to
the practice, presents for his regu-
lar 6-monthly assessment. He is
HIV-positive, and has been on
antiretrovirals for over 3 years. In
1999, he was started on:
• AZT 300 mg po bd
• 3TC 150 mg po bd
• Nevirapine 200 mg po bd.
His initial CD4 count was 118
cells/mm3, and his viral load pre-
Watch out for side-
effects. Encourage
your patient to
come to you before





a d h e r e n c e .
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therapy was 240 000 copies/ml. He
responded well to antiretroviral
therapy, and has had an unde-
tectable viral load (less than 400
copies/ml) since week 24 of therapy.
His last CD4 count (6 months pre-
viously) was 385 cells/mm3. He has
been clinically well. His CD4
count is now 320 cells/mm3, and
his viral load is measured at
18 000 copies/ml.A repeat viral
load in 2 weeks is 20 000
copies/ml, and he is assessed as
failing initial therapy. Excluding
intercurrent illness, recent vaccina-
tion, malabsorption and compli-
ance problems, the most likely
cause of failure is development of
viral resistance to the current regi-
men. He is therefore changed to:
• D4T 40 mg po bd (weight 76
kg)
• DDI 200 mg po bd
• lopinavir/ritonavir 400/100 mg
po bd.
A 6-week viral load is undetectable
(less than 400 copies/ml), and the
minor nausea of the first week of
therapy (probably induced by the
ritonavir) is treated with cyclizine
50 mg bd.
He continues to have an unde-
tectable viral load and increasing
CD4 count at his next 6-month
assessment.
Changing antiretroviral regimens,
particularly when moving from a
first- to a second-line regimen,
generally follows a predictable pat-
tern. Once failure has been deter-
mined, all drugs are altered in
order to get as many ‘clean’ agents
in the new regimen as possible.
The new regimen is constructed
according to the template in case
one above. Backbone: one thymi-
dine analogue NRTI: AZT
changed to D4T; one non-thymi-
dine analogue NRTI: 3TC
changed to DDI; NNRTI class
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H AA RT is very effective tre a t m e n t
for advanced (CD4 count < 2 0 0
cells/µl) or symptomatic HIV infec-
t i o n .
Once initiated, HAA RT must be
continued for life.
Dual therapy should never be pre-
scribed as the benefits are transient
and re s i stance develops quickly.
B e f o re committing to HAA RT
patients should have come to
terms with their HIV infection and
should have the support of family
or friends.
P s y c h o l o g i cal issues and depre s-
sion should be addressed before
H AA RT is commenced.
In advanced HIV infection the risk
of side-effects from HAA RT is out-
weighed by the benefits of viral
s u p p re s s i o n .
The importance of strict adhere n c e
to a HAA RT regimen should be
emphasised, and problems that
may compromise adhere n c e
should be managed pro a c t i v e l y.
Clinicians should have a high index
of suspicion for ART-induced drug
side-effects, especially for lactic aci-
dosis/acidaemia, which has very
nonspecific symptoms including
fatigue, weight loss, nausea, dysp-
noea and abdominal pain. 
SINGLE SUTURE
Graduate v. undergraduate training
Several Australian medical schools have moved to graduate-entry, problem-based programmes and others
are considering changes to their curricula and entry criteria.Who is best prepared for hospital practice —
the graduate-entry students, or the more traditional undergraduate students who also receive problem-
based education? A recent study in the Medical Journal of Australia (2003: 178: 163-166) found that gradu-
ates from the newer approach were less well prepared for their intern year than graduates from the tradi-
tional and undergraduate problem-based programmes.
